SCHEMBL6786240

SCHEMBL6786240

C/C(=C/C(=O)Nc1cc(C(=O)Nc2ccncc2)ccc1C(=O)O)c1ccc2ccccc2c1

nearest known ligand 0.67

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TERT O14746 5/20 0.67
NPC1 O15118 4/20 0.61
RAB9A P51151 4/20 0.61
KDM4E B2RXH2 2/20 0.61
SIRT2 Q8IXJ6 1/20 0.49
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
CASP3 P42574 1/20 0.45
SENP7 Q9BQF6 1/20 0.45
DEGS1 O15121 1/20 0.45
JAK2 O60674 1/20 0.43
TYK2 P29597 1/20 0.43
NR1H4 Q96RI1 1/20 0.43
POLB P06746 1/20 0.43
STAT3 P40763 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
DHODH Q02127 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6785371 0.93 TERT (0.73) TERTNPC1RAB9AKDM4EMEN1
SCHEMBL6786540 0.90 NPC1 (0.58) TERTNPC1RAB9AKDM4ESIRT2
SCHEMBL6787594 0.90 TERT (0.63) TERTNPC1RAB9AKDM4ESIRT2
SCHEMBL6787318 0.87 TERT (0.62) TERTNPC1RAB9AKDM4ENR1H4
SCHEMBL6785021 0.86 TERT (0.78) TERTNPC1RAB9AKDM4EMEN1
SCHEMBL6783732 0.85 TERT (0.85) TERTNPC1RAB9AKDM4EDEGS1
SCHEMBL6781497 0.84 TERT (0.60) TERTNPC1RAB9AKDM4EMEN1
SCHEMBL6786325 0.84 TERT (0.76) TERTNPC1RAB9AKDM4EMEN1
SCHEMBL6792283 0.84 TERT (0.76) TERTNPC1RAB9AKDM4EMEN1
SCHEMBL4024968 0.83 TERT (0.75) TERTNPC1RAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6727250-B2 ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-04-27 US disclosed
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-07-25 US disclosed
US-6362210-B1 ANTITUMOR, ANTICANCER AGENT BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation TERT, NAT1, POT1 TERT 1/4885NPC1 3387/4885RAB9A 2130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.